Bristol Myers Squibb (BMY) Com Stk USD 0.10 (CDI)
Sell:$57.81Buy:$57.84
$1.29
(2.16%)
- This stock can be held in a
Stocks and Shares ISA$1.29
(2.16%)$1.29
(2.16%)Company Information
About this company
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Key people
Key facts
- EPICBMY
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS1101221083
- Market cap$121.17bn
- Employees34,100
- Shares in issue2.93bn
- ExchangeNew York Stock Exchange
- IndexS&P 500, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.